Screening procedures can begin once the informed consent document is signed. These are procedures the protocol requires to be performed to determine if the research participant can be enrolled in the trial. After confirmation of eligibility, the patient is registered and randomized into the trial. The study calendar for the trial stipulates the ongoing tests and treatments the patient will undergo throughout the course of the trial. Ongoing assessments for adverse events are conducted.
Treatment continues until completed per the study parameters, unless:
- Disease progression occurs.
- Unacceptable toxicity is demonstrated.
- The patient expresses the desire to stop therapy.
Ongoing/survival follow up continues as outlined in the study parameters.